Chong Kun Dang Pharmaceutical

• atorvastatin

  HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels

  Approved, Small molecule, AMPK signalling, Lipid and ceramide metabolism, angina, coronary heart disease

• empagliflozin

  Inhibits renal SGLT2 to reduce glucose reabsorption and lower blood glucose

  Approved, Small molecule, AMPK signalling, Autophagy, cardiovascular death, cardiovascular disease

• glimepiride

  Sulfonylurea that stimulates insulin secretion by blocking ATP-sensitive potassium channels in pancreatic beta cells.

  Approved, Small molecule, Insulin/IGF-1 signalling, ABCC8, diabetes mellitus (Phase 3), non insulin dependent diabetes mellitus (Phase 3)

4 more assets